David Kirske - Oct 4, 2022 Form 4 Insider Report for CTI BIOPHARMA CORP (CTIC)

Role
EVP, Chief Financial Officer
Signature
David Kirske
Stock symbol
CTIC
Transactions as of
Oct 4, 2022
Transactions value $
-$11,193
Form type
4
Date filed
10/6/2022, 04:20 PM
Previous filing
Oct 3, 2022
Next filing
Jan 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Options Exercise $1.33K +1.4K +8.28% $0.95 18.3K Oct 4, 2022 Direct
transaction CTIC common stock Sale -$8.75K -1.4K -7.64% $6.25 16.9K Oct 4, 2022 Direct F1
transaction CTIC common stock Options Exercise $94.90 +100 +0.59% $0.95 17K Oct 4, 2022 Direct
transaction CTIC common stock Sale -$626 -100 -0.59% $6.26 16.9K Oct 4, 2022 Direct F1
transaction CTIC common stock Options Exercise $578 +609 +3.6% $0.95 17.5K Oct 4, 2022 Direct
transaction CTIC common stock Sale -$3.82K -609 -3.48% $6.27 16.9K Oct 4, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -1.4K -0.43% $0.00 325K Oct 4, 2022 Common Stock 1.4K $0.95 Direct F2
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -100 -0.03% $0.00 325K Oct 4, 2022 Common Stock 100 $0.95 Direct F2
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -609 -0.19% $0.00 324K Oct 4, 2022 Common Stock 609 $0.95 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
F2 One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.